Almahmoudi, R, Kasanen, M, Sieviläinen, M, et al. Prognostic value of blood and lymphatic vessel markers in tongue cancer: A systematic review. Cancer Sci. 2019; 110: 3424‐ 3433. https://doi.org/10.1111/cas.14189
Prognostic value of blood and lymphatic vessel markers in tongue cancer : a systematic review
|Author:||Almahmoudi, Rabeia1,2; Kasanen, Merimaija1; Sieviläinen, Meri1;|
1Department of Oral and Maxillofacial Diseases, Clinicum, University of Helsinki, Helsinki, Finland
2Translational Immunology Research Program (TRIMM), University of Helsinki, Helsinki, Finland
3Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland
4Department of Public Health, University of Helsinki, Helsinki, Finland
5Department of Mathematics and Statistics, University of Helsinki, Helsinki, Finland
6Cancer and Translational Medicine Research Unit, University of Oulu, Oulu, Finland
7Medical Research Centre, Oulu University Hospital, Oulu, Finland
8HUS, Helsinki University Hospital, Helsinki, Finland
|Online Access:||PDF Full Text (PDF, 0.5 MB)|
|Persistent link:|| http://urn.fi/urn:nbn:fi-fe2019120245231
John Wiley & Sons,
|Publish Date:|| 2019-12-02
Tongue squamous cell carcinoma (TSCC) has a poor prognosis due to its early metastasis through blood and lymphatic vessels. We undertook a systematic review to investigate the prognostic significance of blood microvessel density (MVD) and lymphatic vessel density (LVD) in TSCC patients. We carried out a systematic search in Ovid Medline, Scopus, and Cochrane libraries. All studies that evaluated the prognostic significance of MVD/LVD markers in TSCC were systematically retrieved. Our results showed that MVD/LVD markers, CD31, CD34, CD105, factor VIII, lymphatic vessel endothelial hyaluronan receptor‐1, and D2‐40 were evaluated in TSCC patients until 28 June 2018. Six out of 13 studies reported markers that were associated with poor prognosis in TSCC. Two out of three studies suggested that a high number of D2‐40+ vessels predicated low overall survival (OS); the third study reported that the ratio of D2‐40+ over factor VIII+ vessels is associated with low OS. Most of the other markers had controversial results for prognostication. We found higher expression of MVD/LVD markers were commonly, but not always, associated with shorter survival in TSCC patients. It is therefore not currently possible to recommend implementation of these markers as reliable prognosticators in clinical practice. More studies (especially for D2‐40) with larger patient cohorts are needed.
|Pages:||3424 - 3433|
|Type of Publication:||
A2 Review article in a scientific journal
|Field of Science:||
The authors acknowledge the funders of this study: the Doctoral Program in Clinical Research, University of Helsinki; the Cancer Society of Finland; the Emil Aaltonen Foundation (Emil Aaltosen Säätiö); the Finnish Dental Society (Apollonia); the Sigrid Jusélius Foundation, the Oulu University Hospital MRC grant; and the Helsinki University Central Hospital research funds.
© 2019 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.